Helixmith, 13.32% Up Amid Immune Checkpoint Inhibitor Theme Surge

On the 11th, the immuno-oncology theme rose by 3.10% compared to the previous day, showing strength, while Helixmith, a related stock attracting attention, surged by 13.32% compared to the previous day. Helixmith is known as a company specializing in the development of new drugs centered on gene therapy.

[Graph] Price Fluctuations of Major Stocks in the Immuno-Oncology Theme

According to provisional data compiled at 10:46, Helixmith is experiencing large-scale net selling by institutions, with institutions selling 30,000 shares.

[Table] Net Trading Volume of Foreigners and Institutions (Unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Helixmith’s quant financial score is 0.65, ranking 21st in the quant financial ranking within the immuno-oncology theme. This can be interpreted as Helixmith having relatively low investment attractiveness from a financial perspective. On the other hand, Dong-A ST ranked first in the quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top Stocks by Financial Score within the Theme

※ The quant financial score is the result of the robo algorithm analyzing each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.